STONY BROOK, NY / ACCESS Newswire / July 24, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (“Applied DNA” or the “Company”) ...

The FDA accepted a resubmitted new drug application for reproxalap, a first-in-class investigational topical therapy for dry ...

The Trump administration’s proposed cuts at the National Institutes of Health and Food and Drug Administration could lower ...

GoodRx reports that in 2025, novel drug and biosimilar approvals lag slightly behind last year, while first generic approvals ...

Researchers at the National University of Singapore (NUS) have found new applications of magnetic field therapy with ...

The submission is supported by four Phase III clinical trials, which showed that icotrokinra demonstrated significant skin ...

The corner of 31st Avenue and 12th Street was the target location for the Gulfport branch of Mississippi Drug and Alcohol ...

Lupin receives USFDA approval for generic diabetes medications, including Liraglutide Injection and Glucagon for Injection.

ODMAP in Yakima County went live in March 2024, first with law enforcement agencies entering data through the Spillman record ...

Sotyktu (deucravacitinib) has been assigned a Prescription Drug User Fee Act (PDUFA) goal date of March 6, 2026.

In a complete response letter, the FDA indicates the drug trial is not an adequate, well-controlled clinical investigation, ...

SHELTON, CT / ACCESS Newswire / July 21, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.: NNVC ) (the ...